Name | Number of supported studies | Average coverage | |
---|---|---|---|
fibroblast | 3 studies | 19% ± 2% | |
mucus secreting cell | 3 studies | 47% ± 19% |
Insufficient scRNA-seq data for expression of CBR3 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
prostate | 100% | 262.95 | 245 / 245 | 99% | 13.61 | 495 / 502 |
skin | 99% | 406.72 | 1798 / 1809 | 97% | 16.49 | 460 / 472 |
breast | 100% | 343.82 | 459 / 459 | 96% | 12.53 | 1078 / 1118 |
brain | 97% | 203.30 | 2551 / 2642 | 95% | 7.15 | 670 / 705 |
uterus | 100% | 235.05 | 170 / 170 | 87% | 16.75 | 401 / 459 |
bladder | 100% | 295.95 | 21 / 21 | 87% | 9.21 | 438 / 504 |
esophagus | 100% | 633.17 | 1442 / 1445 | 79% | 7.66 | 145 / 183 |
lung | 83% | 103.67 | 479 / 578 | 85% | 12.94 | 984 / 1155 |
thymus | 91% | 126.89 | 593 / 653 | 76% | 3.95 | 460 / 605 |
intestine | 95% | 169.49 | 919 / 966 | 67% | 3.98 | 353 / 527 |
ovary | 99% | 253.84 | 179 / 180 | 44% | 2.07 | 188 / 430 |
stomach | 65% | 107.77 | 232 / 359 | 53% | 2.19 | 152 / 286 |
eye | 0% | 0 | 0 / 0 | 100% | 14.09 | 80 / 80 |
tonsil | 0% | 0 | 0 / 0 | 100% | 19.66 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 3.92 | 1 / 1 |
adipose | 100% | 387.43 | 1202 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 336.30 | 1330 / 1335 | 0% | 0 | 0 / 0 |
pancreas | 7% | 5.60 | 23 / 328 | 85% | 4.30 | 152 / 178 |
kidney | 44% | 51.65 | 39 / 89 | 47% | 2.04 | 419 / 901 |
adrenal gland | 40% | 37.55 | 103 / 258 | 40% | 1.81 | 93 / 230 |
lymph node | 0% | 0 | 0 / 0 | 72% | 4.48 | 21 / 29 |
heart | 72% | 81.19 | 619 / 861 | 0% | 0 | 0 / 0 |
spleen | 67% | 64.55 | 161 / 241 | 0% | 0 | 0 / 0 |
muscle | 19% | 15.86 | 150 / 803 | 0% | 0 | 0 / 0 |
liver | 0% | 0.49 | 1 / 226 | 15% | 0.74 | 62 / 406 |
peripheral blood | 3% | 2.52 | 27 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0050890 | Biological process | cognition |
GO_0042376 | Biological process | phylloquinone catabolic process |
GO_0006805 | Biological process | xenobiotic metabolic process |
GO_0005615 | Cellular component | extracellular space |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005829 | Cellular component | cytosol |
GO_0004090 | Molecular function | carbonyl reductase (NADPH) activity |
GO_0008753 | Molecular function | NADPH dehydrogenase (quinone) activity |
GO_0070402 | Molecular function | NADPH binding |
GO_0005515 | Molecular function | protein binding |
GO_0000253 | Molecular function | 3-keto sterol reductase activity |
Gene name | CBR3 |
Protein name | Carbonyl reductase [NADPH] 3 (EC 1.1.1.184) (NADPH-dependent carbonyl reductase 3) (Quinone reductase CBR3) (EC 1.6.5.10) (Short chain dehydrogenase/reductase family 21C member 2) |
Synonyms | SDR21C2 |
Description | FUNCTION: Catalyzes the NADPH-dependent reduction of carbonyl compounds to their corresponding alcohols . Has low NADPH-dependent oxidoreductase activity. Acts on several orthoquinones, acts as well on non-quinone compounds, such as isatin or on the anticancer drug oracin . Best substrates for CBR3 is 1,2- naphthoquinone, hence could play a role in protection against cytotoxicity of exogenous quinones . Exerts activity toward ortho-quinones but not paraquinones. No endogenous substrate for CBR3 except isatin has been identified . . |
Accessions | O75828 ENST00000290354.6 |